- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03482362
Vinorelbine in Advanced BRAF-like Colon Cancer (EORTC1616)
MoTriColor: A Phase II Study of Vinorelbine in Advanced BRAF-like Colon Cancer
Vecchione et al showed that suppression of RANBP2 results in mitotic defects only in BRAF-like colon cancer (CC) cells, which leads to cell death. Mechanistically, RANBP2 silencing reduces microtubule outgrowth from the kinetochores, thereby inducing spindle perturbations, providing an explanation for the observed mitotic defects. Vinorelbine mimics RANPB2 silencing in BRAF-like and BRAFV600E CC cell lines.
These preclinical data represent a strong rationale to also explore the anti-tumor activity of vinorelbine in patients with advanced BRAF-like (both BRAFm and BRAF wild type) CC. Tumors having this gene signature are referred to as "BRAF-like" and have a similar poor prognosis irrespective of the presence of BRAF(V600E) mutation. Since vinorelbine is standard of care in advanced breast and NSCLC, there is ample experience with the dose and schedule as well as with the safety profile and supportive measures required to prevent side-effects.
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: N Steeghs, MD, PhD
- Phone Number: +31(0)20-5129111
- Email: n.steeghs@nki.nl
Study Contact Backup
- Name: Sanne Huijberts, MD
- Phone Number: +31(0)20-5129111
- Email: s.huijberts@nki.nl
Study Locations
-
-
Noord-Holland
-
Amsterdam, Noord-Holland, Netherlands, 1066 CX
- Recruiting
- Antoni van Leeuwenhoek
-
Contact:
- Sanne Huijberts, MD
- Phone Number: +312051291111
- Email: s.huijberts@nki.nl
-
Contact:
- N Steeghs, MD, PhD
- Phone Number: +312051291111
- Email: n.steeghs@nki.nl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent for this clinical trial (+ TR (translational research)) must be given according to ICH/GCP and national/local regulations
- Written documentation of BRAF-like signature CC, including BRAFm and BRAFwt, as determined by the validated assay of Agendia
- Written documentation of KRAS and BRAF mutational status.
- Age > 18 years
- Histologically proven and measurable (RECIST criteria v.1.1) metastatic adenocarcinoma of the colon not in a previously irradiated area, treated with at least one or two lines of standard of care therapy, including BRAF inhibitors, for advanced disease
- WHO performance status of 0-1
- Able and willing to undergo blood sampling for pharmacodynamic (PD) analysis;
- Able and willing to undergo tumor biopsy prior to, during and upon treatment;
- Life expectancy > 3 months allowing adequate follow up of toxicity evaluation and antitumor activity
Minimal acceptable safety laboratory values:
- ANC > 1.5 x 109 /L
- Platelet count > 100 x 109 /L
- Hemoglobin > 6.0 mmol/L
- Hepatic function as defined by serum bilirubin < 1.5 x ULN, ALAT and ASAT < 2.5 x ULN, or ALAT and ASAT < 5 x ULN in patients with liver metastases
- Renal function as defined by serum creatinine < 1.5 x ULN
- creatinine clearance > 50 ml/min (by Cockcroft-Gault formula)
- Negative urine or serum pregnancy test (serum or urine) for female patients with childbearing potential
Exclusion Criteria:
- Any treatment with investigational drugs, including BRAF inhibitors, within 28 days prior to receiving the first dose of investigational treatment
- Symptomatic or untreated leptomeningeal disease
- Symptomatic brain metastasis. Patients previously treated or untreated for these conditions that are asymptomatic in the absence of corticosteroid and anticonvulsant therapy (for at least 4 weeks) are allowed to enroll. Radiotherapy for brain metastasis must have been completed at least 6 weeks prior to start of study treatment. Brain metastasis must be stable with verification by imaging (e.g. brain MRI or CT completed at screening (<21 days before start of treatment) demonstrating no current evidence of progressive brain metastases). Patients are not permitted to receive enzyme inducing anti-epileptic drugs or corticosteroids.
- Impairment of gastrointestinal (GI) function or GI disease (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, any condition inducing malabsorption, small bowel resection)
- Other uncontrolled concomitant illness, including serious uncontrolled intercurrent infection
- Known allergy or any other adverse reaction to any of the drugs or to any related compound
- Women who are pregnant or breast feeding
- Unreliable contraceptive methods. Both men and women enrolled in this trial must agree to use a reliable contraceptive method throughout the study (adequate contraceptive methods are: condom, sterilization, other barrier contraceptive measures preferably in combination with condoms) 9. Radio-, immuno- or chemotherapy within the last 4 weeks prior to receiving the first dose of investigational treatment. Palliative radiation (1x 8Gy) is allowed
10. Patients who have undergone any major surgery within the last 2 weeks prior to starting study drug or who would not have fully recovered from previous surgery 11. Uncontrolled infectious disease or known Human Immunodeficiency Virus HIV-1 or HIV-2 type patients 12. Patients with a known history of hepatitis B or C 13. Patients with cardiac comorbidities (myocardial infarct within 6 months of study start, NYHA class ≥ III, congestive heart failure or instable angina pectoris), uncontrolled hypertension (systolic blood pressure > 150 mm Hg and/or diastolic pressure > 90 mm Hg) or prolonged QT-interval (> 440 ms for men, > 460 ms for women) 14. Other severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration or that may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for the study 15. Known hypersensitivity to study drug or excipients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Cohort A; KRASmt, BRAFwt, BRAF-like CC
Patients with KRAS mutant and BRAF wildtype colon cancer that met the BRAF-like signature according to the validated test of Agendia will be treated with vinorelbine tartrate.
|
Intravenous administration of vinorelbine on day 1 and day 8 in a dose of 30 mg/m2.
One treatment cycle is 21 days.
Other Names:
|
EXPERIMENTAL: Cohort B; KRASwt, BRAFmt, BRAF-like CC
Patients with KRAS wildtype and BRAF mutant colon cancer that met the BRAF-like signature according to the validated test of Agendia will be treated with vinorelbine tartrate.
|
Intravenous administration of vinorelbine on day 1 and day 8 in a dose of 30 mg/m2.
One treatment cycle is 21 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Doubling of progression free survival
Time Frame: 15 months
|
This means that by vinorelbine treatment the rate of progression drops to 25%.
|
15 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence and severity of adverse events
Time Frame: 15 months
|
15 months
|
|
Overall response rate
Time Frame: 15 months
|
15 months
|
|
Duration of response
Time Frame: 15 months
|
15 months
|
|
Time to response
Time Frame: 15 months
|
15 months
|
|
Overall survival
Time Frame: 15 months
|
15 months
|
|
Baseline molecular status (mutation/ expression) in tumor tissue of potential predictive markers of tumor response
Time Frame: 15 months
|
The molecular status will be measured by NGS and IHC in tumor tissue.
|
15 months
|
Gene alterations/expression profiles (i.e. baseline, relapse) in tumor tissue upon progression
Time Frame: 15 months
|
The molecular status will be measured by NGS and IHC in tumor tissue.
|
15 months
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall response rate of vinorelbine in patients with KRAS mutant, BRAF wildtype, BRAF-like colon cancer vs. KRAS wildtype, BRAF mutant, BRAF-like colon cancer.
Time Frame: 15 months
|
15 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: N Steeghs, MD, PhD, NKI-AVL
- Principal Investigator: F Ciardiello, Prof, INCLIVA
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Neoplasms by Site
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Colonic Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Colorectal Neoplasms
- Colonic Neoplasms
- Molecular Mechanisms of Pharmacological Action
- Antineoplastic Agents
- Tubulin Modulators
- Antimitotic Agents
- Mitosis Modulators
- Antineoplastic Agents, Phytogenic
- Vinorelbine
Other Study ID Numbers
- M16VIB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colon Cancer
-
National Cancer Institute (NCI)NSABP Foundation IncCompletedColon Adenocarcinoma | Stage IIIA Colon Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage IIIC Colon Cancer AJCC v7 | Stage IIA Colon Cancer AJCC v7 | Stage IIB Colon Cancer AJCC v7 | Stage IIC Colon Cancer AJCC v7United States
-
Gruppo Oncologico del Nord-OvestSeagen Inc.; Servier; Foundation MedicineRecruitingStage II Colon Cancer | Stage III Colon Cancer | HER2-positive Colon Cancer | RAS Wild-type Colon CancerItaly
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
-
Vanderbilt-Ingram Cancer CenterNational Cancer Institute (NCI)CompletedFatigue | Depressive Symptoms | Stage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Psychosocial Effects of Cancer and Its Treatment | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage I Colon Cancer | Stage... and other conditionsUnited States
-
Hospital da Senhora da OliveiraCompletedColon Cancer | Colon Adenoma | Colon Polyp | Colon Rectal CancerPortugal
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)RecruitingStage III Colon Cancer AJCC v8 | Colon Adenocarcinoma | Microsatellite Stable Colon Carcinoma | Stage IIB Colon Cancer AJCC v8 | Stage IIC Colon Cancer AJCC v8United States
-
National Cancer Institute (NCI)CompletedStage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer | Stage IVB Colon Cancer | Stage IVB Rectal CancerUnited States
-
Howard S. Hochster, MDRecruitingStage IV Colon Cancer AJCC v8 | Stage IVA Colon Cancer AJCC v8 | Stage IVB Colon Cancer AJCC v8 | Stage IVC Colon Cancer AJCC v8 | Metastatic Colon CarcinomaUnited States
-
NorgineXolomon Tree S.L.CompletedColon Cancer | Colon Disease | Colon CleansingSpain, Portugal
Clinical Trials on Vinorelbine Tartrate
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
GlaxoSmithKlineCompletedLung CancerUnited States, Canada, Puerto Rico
-
H. Lee Moffitt Cancer Center and Research InstituteNational Cancer Institute (NCI)UnknownUnspecified Adult Solid Tumor, Protocol SpecificUnited States
-
Metronome TherapeuticsUnknownNonhematologic MalignanciesUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Swiss Group for Clinical Cancer ResearchCompleted
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical CancerUnited States
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Medical Research CouncilCompleted
-
Mast Therapeutics, Inc.Worldwide Clinical Trials; Synteract, Inc.; Thywill Latam Solutions SRL; OCASA...CompletedA Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.Breast Cancer | Non-small Cell Lung Cancer | Non-Hodgkins LymphomaArgentina